Clinical Trial Update: Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CERC-002 for adults with COVID-19 pneumonia and acute lung injury has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia
• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• CERC-002 (null)

Snippet

Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company | Conditions: COVID-19 Pneumonia, Acute Lung Injury | Phase 2 | Status: COMPLETED | Results posted: 2022-03-04